Inhibikase Therapeutics Reports Q3 2026 Results, $20.5M Net Loss

Inhibikase Therapeutics reported a net loss of $20.5 million for the third quarter of 2026, compared with $11.9 million a year earlier. Cash, cash equivalents and marketable securities totaled $193.3 million at September 30, 2026. The company said its Phase 3 IMPROVE-PAH study had regulatory approv…